MTOR and acute myeloid leukemia: PIM kinase signaling takes part in various pathways to define cell fate, including senescence, cell cycle regulation, apoptosis, metabolism, invasion, and metastasis; thus the combination of a PIM kinase inhibitor with an mTOR inhibitor is expected to offer greater antitumor effects in AML than either inhibitor alone [18].